Stocks To Watch With Next Quarterly Report On Tap: Vertex PharmaceuticalsInvestors Business Daily • 07/24/20
Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks24/7 Wall Street • 07/24/20
Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function MutationBusiness Wire • 07/20/20
Tax software company Vertex to offer 21.2 million shares in planned IPO, priced at $14 to $16 eachMarket Watch • 07/20/20
Vertex Pharmaceuticals Selects TRIA to Design Laboratory and Office for New 268,000 SF VCGT Research SitePRNewsWire • 07/16/20
Vertex Pharmaceuticals (VRTX) Stock Moves -0.18%: What You Should KnowZacks Investment Research • 07/09/20
5 Greenblatt Magic Formula Biotech Stocks to Weather the Summer Coronavirus StormGuruFocus • 07/07/20
Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy ZonesInvestors Business Daily • 07/03/20
Vertex Announces Expansion of Reimbursement Agreement With NHS England to Include KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor)Business Wire • 06/30/20
Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?Zacks Investment Research • 06/29/20
CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With KALYDECO® (ivacaftor) in People Ages 12 and Older With Cystic Fibrosis With the Most Common GenotypesBusiness Wire • 06/26/20